Close Menu

NEW YORK – Thermo Fisher Scientific and Qiagen said today that they have amended the terms of their acquisition agreement, raising the offer price for Qiagen's stock to €43 ($49) per share to "reflect the fair value of the business."

Under the original agreement, announced March 3, Thermo Fisher was going to pay €39 per Qiagen share, a 23 percent premium over the closing price of Qiagen's common stock on March 2. The amendment raises the premium to 35 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.